Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version
- 23 October 2008
- journal article
- practice guideline
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 13 (5), 416-430
- https://doi.org/10.1007/s10147-008-0798-7
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma GroupJournal of Clinical Oncology, 2007
- Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GISTAnnals of Surgery, 2007
- Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal TumorAnnals of Surgery, 2007
- Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal TumorsAnnals of Surgery, 2006
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mgEuropean Journal of Cancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998